the 13G filing simply states that they now own more than 5% of the outstanding shares, some 5+ million, don't remember the exact number. If you go back and look at what they previously held, you'll see that they added over a million shares to their previous position, which put them over the 5% limit that requires them to disclose their total stake in the company.
Been saying that all along. SYN will develop the US market and partner for Europe, Middle East and Asia. So many partnerships yet to come and you know what that does to PPS
I'm far from a technical guru....I just call it like I see it, been right more than wrong, but far from perfect. I try to use it to trade in and out of SYN (to grow my share count in my 401k). Though many on this board gave Dallas #$%$, he was pretty good, even if you didn't like what he said.
nasdaq says $3.21, yahoo says$3.21.....I think I'll choose to believe them. But honestly, what does it really matter? For such low volume, it doesn't mean jack poop.
What matters is that you're not going to see much lower that what you saw today....you should have covered when it hit $3....your hoping that it will get down there again is just that, hope. You're better off covering at $3.15 and going long for the ride up....just saying.
You really need to get out of your dingy basement and into the light.....after hours at 8:00 is $3.21 for a whopping 1,700 shares
The triangle is typically a continuation pattern, which would indicate a move to the upside. What was a bit confusing today was that the low of today breached the lower trend line, albeit on low volume. This could be a signal for retesting the $3 mark again, or it could just be nothing. As it stands now, you'll get maybe one more day of trading in (Wed) before we hit the intersection of the upper and lower trend lines, which would typically cause a break in one direction or the other. My gut tells me it will be a continuation on the upside, but tomorrow or Thursday will be the tell.
If you look close, you will also see a 5 day falling wedge which gives me some degree of confidence of the upward move.
I know poomeister is a she, makes no difference. Sh'e just playing with fire shorting SYN for pennies when there could be PR any time that gaps this up $$'s at the open and then she will really be rub & tug screwed.
The pattern is even shifting around from highs in the early am and lows mid day to highs mid day and lows just before close, so not even easy to day trade
Oh my gosh....would you look at that....back to the $3.20's again.
Oh....and still hasn't hit that $3.00 mark again has it.....looks like you missed your chance to cover at the low ey. The question is, do you have the marbles to hold your short position for the week?
Ya'll know I'm very pro SYN and long as long can be, but we dipped below the support line on the triangle, which makes me concerned that we may see a bit of downward motion, but I could be wrong....hope so.
So, please tell.....who is the "biggest" name neurologist on the east coast? Also, I believe everyone hear knows of the market limitations of Estriol. However, with Trimesta being the only pharmaceutical to potentially show the capability of improving cognition, there will be plenty of opportunity for pharma to offer this in combination with their stable of drugs and have a significant impact in the market.
BTW, I am in it to win it with 004 as well, but don't sell short the potential of Trimesta and SYN's rights to all autoimmune diseases. RA by itself is as big, if not bigger than MS.
Hey Poomeister.....today is your last chance to cover at these low prices. The wedge/triangle is about to breakout on the upside leading into the conference call of the 10th. Cover NOW or loose your shorts :-)
OK....let's just look at the MS market for now. If you were to assume that a partner could achieve top line sales of some combination of Trimesta and their drug(s) of $7 Billion after 5 years (which is on the high side IMO) and the Royalty were to be 15%, The NPV of an upfront payment, milestone payments and royalties would be in the $2Billion area. This would be split 60/40 with UCLA, giving SYN $1.2B, or $13.79/share which, based upon history would probably be double this amount or $26/share.
Now if you were to look at other areas autoimmune possibilities, you would just add onto the above....how much, is up to you.
The folks that results and data mean the most to are the potential partners. The publication of the results would have an impact on investors as it would give a bit more clarity on the potential of a partnership, but ultimately, the big driver of the valuation will be the occurrence of the deal. And, I say again, for a deal to take place, it does NOT need any publication of results. It "just" needs the potential partner(s) to have access to the data and the analysis of the data.
Hey Liz, I agree with you. I believe SYN will sell it's rights to Trimesta as it just doesn't fit within the space that they are focusing on. If that is the case, then Dr V's publication becomes a moot point. SYN is free to share any and all information under a CDA which is more than enough for a big Pharma to make a decision on the valuation of Trimesta in order to make an offer to SYN. As an investor, I would actually prefer this scenario as it would fund future clinical trials as well as accelerate other pre-clinical trials, including 005. If that is the case, it will be very interesting to see what it ends up getting valued at.